Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Pharmactive Biotech Products, SLU, a leading provider of natural extracts, proudly announces its official certification as a B Corporation, underscoring its unwavering commitment to maintaining elevated standards in social and environmental performance, transparency, and overall business excellence.
read more
The Global Pharmaceutical Grade Lithium Carbonate Market is projected to grow from USD 141 million in 2023 to USD 166 million by 2028, at a CAGR of 3.3% from 2023 to 2028, as per the recent study by MarketsandMarkets™.
read more
The global active pharmaceutical ingredients (API) market is projected to increase at a CAGR of 6.4% from 2023 to 2031. As per the report published by TMR, a valuation of US$ 331.3 billion is anticipated for the market in 2031. As of 2023, the demand for active pharmaceutical ingredients (API) will close at US$ 202.3 billion.
read more
Boncha Bio has proudly unveiled a strategic alliance with dsm-firmenich in Asia, a global leader in innovation spanning nutrition, health, and beauty. This momentous collaboration was formalized on September 21st during the Vitafoods Asia 2023 exhibition in Bangkok, Thailand.
read more
Viriom Inc. announced the successful conclusion of Phase I clinical trials for AV5124, an innovative inhibitor designed to target influenza virus replication. AV5124 has proven to be an exceptionally effective inhibitor of influenza virus RNA processing, exhibiting potency against various influenza types, including those resistant to neuraminidase ...
read more
Romaco Pharmatechnik GmbH in Karlsruhe welcomes Boris Bachmeier as its new Managing Director, succeeding Markus Regner, who, by his own request, will be departing the company at the end of November.
read more
Pro Doc Limitée has initiated a recall of a specific lot of Donepezil (donepezil hydrochloride) 10 mg tablets, citing concerns that certain bottles may contain oversized tablets. Health Canada is cautioning patients and their caregivers about the potential risks associated with taking an oversized tablet, which could result in receiving up to three...
read more
Ogsiveo (nirogacestat) tablets have received approval from the Food and Drug Administration for use in adult patients with progressing desmoid tumors requiring systemic treatment. Marking a milestone, Ogsiveo becomes the inaugural drug sanctioned for addressing desmoid tumors, a rare subset of soft tissue sarcomas.
read more
Meta Herbal is initiating a recall of Magnum XXL 9800 2000 mg per capsule due to the detection of undeclared sildenafil in the products.
read more
Amneal Pharmaceuticals, Inc. and Strides Pharma Science Limited have jointly announced the introduction of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®.
read more
Phathom Pharmaceuticals, Inc. has proudly disclosed that the FDA accepted the New Drug Application (NDA) for VOQUEZNA (vonoprazan).
read more
Vanda Pharmaceuticals Inc. announced that it has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. PONVORY® is approved by the US FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, ...
read more
Tilde Sciences, a specialty pharmaceutical company, announced that it has acquired two medicines, Daraprim® and Vecamyl® from Vyera Pharmaceuticals.
Tilde Sciences expects a seamless transition from Vyera Pharmaceuticals and uninterrupted access through Optime Care, its specialty pharmacy partner.
read more
Biora Therapeutics, Inc. announced a new research collaboration with a large pharmaceutical company for its BioJet™ Systemic Oral Delivery Platform. The new agreement provides funding to test the BioJet platform’s ability to achieve bioavailability through oral delivery of the undisclosed collaborator’s molecules to the small intestine in animal ...
read more
USWM, LLC announced that the FDA approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk neuroblastoma. IWILFIN is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality ...
read more